Advertisement

90. Kongreß pp 656-675 | Cite as

Hepatologie I

  • A. Doermer
  • E. Ungeheuer
  • M. Goerig
  • A. Habenicht
  • U. Tochtermann
  • B. Kommerell
  • B. Braun
  • P. Meyer
  • N. Börner
  • H. Klusemann
  • J. Reuß
  • M. Rothmund
  • H. Schomerus
  • R. Heinrich
  • W. Grauer
  • A. Huber
  • W. Fleckenstein
  • Ch. Weiss
  • E. Musch
  • R. Stiens
  • W. K. Lelbach
Conference paper
Part of the Verhandlungen der Deutschen Gesellschaft für Innere Medizin book series (VDGINNERE, volume 90)

Zusammenfassung

Die Leberzirrhose stellt zur Zeit die dritthäufigste Todesursache bei Männern dar. In der Mehrzahl der Fälle steht der Alkoholismus kausal am Anfang einer Entwicklung, deren weiterer Verlauf unabwendbar und schicksalshaft vorbestimmt erscheint. Rezidivierende Ösophagusvarizenblutungen und die schrittweise Verschlechterung der Leberfunktion bis zum Coma hepaticum führen schließlich den letalen Ausgang herbei. Grund für diesen allgemein geteilten Pessimismus ist die Tatsache, daß eine therapeutische Beeinflussung der Leberzirrhose als der zugrundeliegenden Erkrankung weiterhin nicht in Sicht ist und somit jedes Therapieverfahren lediglich symptomatischen Charakter hat.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Chaimovitz C, Rochman J, Eidelman S, Better OS (1977) Exaggerated natriuretic response to volume expansion in patients with primary biliary cirrhosis. Am J Med Sci 274: 173–178PubMedCrossRefGoogle Scholar
  2. Sherlock S, Scheuer PJ (1973) The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med 289: 674–678PubMedCrossRefGoogle Scholar
  3. Zipser RD, Little T, Ziperovich H, Duke R (1983) The role of arachidonic acid metabolites in the functional renal impairment associated with liver disease. In: Dunn MJ, Patrono C, Cinotti GA (eds) Prostaglandins and the kidney. Plenum Medical Book Company, New York London, p 263CrossRefGoogle Scholar
  4. 1.
    Clark RA, Matsui O (1983) CT of liver tumors. Semin Roentgenol 18: 149PubMedCrossRefGoogle Scholar
  5. 2.
    Edmondson HA, Peters RL (1983) Tumors of the liver: Pathologic features. Semin Roentgenol 18: 75PubMedCrossRefGoogle Scholar
  6. 3.
    Freeny PC (1983) Angiography of hepatic neoplasms. Semin Roentgenol 18: 114PubMedCrossRefGoogle Scholar
  7. 4.
    Kerlin P et al. (1983) Hepatic adenoma and focal nodular hyperplasia: Clinical, pathologic, and radiologic features. Gastroenterology 84: 994PubMedGoogle Scholar
  8. 5.
    Rogers JV et al. (1981) Hepatic focal nodular hyperplasia: Angiography, CT, sonography, and scintigraphy. Am J Roentgenol 137Google Scholar
  9. 6.
    Taylor KJW, Richman TS (1983) Diseases of the liver. Semin Roentgenol 18: 94PubMedCrossRefGoogle Scholar
  10. 1.
    Kontos HA, Shapiro W, Mauck HP, Patterson JL (1964) General and regional circulatory alterations in cirrhosis of the liver. Am J Med 37: 526–534PubMedCrossRefGoogle Scholar
  11. 2.
    Bayley TJ, Segel N, Bishop JM (1964) The circulatory changes in patients with cirrhosis of the liver at rest and during exercise. Clin Sci 26: 227–235PubMedGoogle Scholar
  12. 3.
    Schomerus H, Buchta I, Arndt H (1975) Pulmonary function studies and oxygen transfer in patients with liver cirrhosis and different degrees of portasystemic encephalopathy. Respiration 32: 1–20PubMedCrossRefGoogle Scholar
  13. 4.
    Arndt H, Buchta I, Schomerus H (1975) Analysis of factors determining the resistance to diffusion in patients with liver cirrhosis. Respiration 32: 21–31PubMedCrossRefGoogle Scholar
  14. 5.
    Gordon MJ, del Guercio LRM (1972) Late effects of portal systemic shunting procedures on cardiorespiratory dynamics in man. Ann Surg 176: 672–679PubMedCrossRefGoogle Scholar
  15. 6.
    Siegel JH, Goldwyn RM, Farrell HJ, Gallin P, Friedman H (1974) Hyperdynamic states and the physiologic determinants of survival. Arch Surg 108: 282–292PubMedCrossRefGoogle Scholar
  16. 7.
    Fleckenstein W, Weiss Ch (1984) A comparison of p02-histograms from rabbit hind limb muscle obtained by simultaneous measurements with hypodermic needle electrodes and with surface electrodes. Sixth Int. Soc. of Oxygen Transport to Tissue. Adv Exp Med Biol (in press)Google Scholar
  17. 8.
    Fleckenstein W, Weiss Ch (1982) Evaluation of p02-histograms obtained by hypodermic needle electrodes. Proceedings World Congress on Medical Physics and Biomedical Engineering, 1982Google Scholar
  18. 9.
    Fleckenstein W, Heinrich R, Grauer W, Schomerus H, Dölle W, Weiss Ch (1984) Fast local regulations of muscle p02-fields in patients suffering from cirrhosis of the liver. Seventh Int. Soc. of Oxygen Transport to Tissue. Meeting 1983. Adv Exp Med Biol (in press)Google Scholar
  19. 10.
    Roughton FJW, Forster RE (1957) Relative importance of diffusion and chemical reaction rates determining rate of exchange of gases in the human lung, with special reference to true diffusing capacity of pulmonary membrane and volume of blood in the lung capillaries. J Appl Physiol 11: 290–302PubMedGoogle Scholar
  20. 11.
    Silverstein E (1956) Peripheral venous oxygen saturation in patients with and without liver disease. J Lab Clin Med 47: 513–518PubMedGoogle Scholar
  21. 12.
    Ehrly AM, Schroeder W (1979) Zur Pathophysiologie der chronisch arteriellen Verschlußerkrankung. I. Mikrozirkulatorische Blutverteilungsstörung. Herz/Kreislauf 11: 275–281Google Scholar
  22. 1.
    Remmer H (1983) Ursachen von Leberschädigungen durch Arzneimittel. Med Monatsschr Pharm 6: 99–107PubMedGoogle Scholar
  23. 2.
    Mitchell JR, Nelson SD, Thorgeirrson SS, McMurtry RJ, Dybing E (1976) Metabolic activation: Biochemical basis for many drug-induced liver injuris. In: Popper, Schaffner (eds) Prog Liver Dis 5: 259–279Google Scholar
  24. 3.
    Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR (1975) Isoniazid-associated hepatitis in 114 patients. Gastroenterology 69: 289–302PubMedGoogle Scholar
  25. 4.
    Riska N (1976) Hepatitis cases in isoniazid treated groups and in a control group. Bull Int Union Tuberc 51: 203–208PubMedGoogle Scholar
  26. 5.
    Emerit J, Decroix G, Chomette G, Periè C, Pessayre D (1974) Donnèes nouvelles sur les hepatites observèes oau cours des traitements antituberculeux incluant la rifampicine. Rev Franc Mal Resp 2: 565–584Google Scholar
  27. 6.
    Brouet G, Modai I, Vegez P (1969) Essais cliniques de la rifampicine en monotherapie. Rev Tuberc (Paris) 33: 27–42Google Scholar
  28. 7.
    Musch E, v. Oldershausen HF (1978) Klinik und Pathogenese der „INH-Hepatitis“. Therapiewoche 28: 3267–3276Google Scholar
  29. 8.
    Musch E, Eichelbaum M, Wang JK, v. Sassen E, Castro-Parra, M, Dengler HJ (1982) Die Häufigkeit hepatotoxischer Nebenwirkungen der tuberculostatischen Kombinationstherapie (INM, RMP, EMB) in Abhängigkeit vom Acetyliererphänotyp. Klin Wochenschr 60: 513–519Google Scholar
  30. 9.
    Wang JK, Musch E, Eichelbaum M, v. Sassen W, Castro-Parra M, Schwabe HK, v Oldershausen HF, Dengler HJ (1983) Continued rifampicin, therapy in cases with severe INH-hepatitis indicating low risk of rifampicin hepatotoxicity. Proceedings 13th Int. Congress of Chemotherapy, 28th Aug. —2nd Sept 1983, Vienna. SE 7.22/1 Part 72, pp 32–36Google Scholar
  31. 10.
    British Medical Research Council (1973) Co-operative controlled trial of a standard regimen of streptomycin, PAS and isnoniacid and three alternative regimens of chemotherapy in Britain. Tubercle 54: 99Google Scholar
  32. 11.
    Lees AW, Allan GP, Smith I (1971) Toxicity from rifampicin plus ethambutol therapy. Tubercle 52: 182–189PubMedCrossRefGoogle Scholar
  33. 12.
    Lees A, Allan GB, Smith J, Tyrell WF, Fallon RS (1972) Rifampicin plus isnoiazid in initial therapy of pulmonary tuberculosis and rifampicin and ethambutol in retreatment cases. Chest 61: 579–582PubMedGoogle Scholar
  34. 13.
    Le Guillou M, L’Henaff F, Boissau M, Castaing J, Bourdalle-Badie Ch (1981) Insuffisance hèpatique aiguè reversible après traitement par l’association isoniazide-rifampicine. Sem Hop Paris 57: 1199–1201PubMedGoogle Scholar
  35. 14.
    Pessayre D, Bentata M, Degott C, Nouel O, Miguet JPh, Rueff B, Benhamou JP (1977) Isoniazid-rifampin fulminant hepatitis. Gastroenterology 72: 284–289PubMedGoogle Scholar
  36. 15.
    Musch E, Eichelbaum M, v. Sassen B, Castro-Parra M, Wang JK, Dengler HJ (1983) Isoniazid-Hepatitis. Verh Dtsch Ges Inn Med 89: 1305–1321Google Scholar
  37. 16.
    U.S. Public Health Service Tuberculosis Therapy Trial (1959) Sequential use of paired combinations of isonizide, streptomycin, paraminosalicylic acid and pyracinamide. Am Rev Respir Dis 80: 627–640Google Scholar
  38. 17.
    Jaeger RL, Munroe WEC, Dessau FJ (1952) Pyracinamide (atchinamide) in treatment of pulmonary tuberculosis. Am Rev Tuberc 65: 523–534Google Scholar
  39. 18.
    McDermaott B, Ormond L, Muschenheim C, Deuschle K, McLune RM Jr, Tompsett R (1954) Pyracinamide-isoniazide in tuberculosis. Am Rev Tuberc 69: 319–333Google Scholar
  40. 19.
    Danan G, Pessyre D, Larrey D, Benhamou JP (1981) Pyracinamide fulminant hepatitis: an old hepatotoxin strikes again. Lancet 2: 1056–1057PubMedGoogle Scholar
  41. 20.
    Conn HO, Binder HJ, Orr HD (1964) Ethionamid-induced hepatitis. A review with a report of an additional case. Am Rev Respir Dis 90: 542PubMedGoogle Scholar
  42. 21.
    Kuntz E, Liehr H, Pfingst W (1967) Toxische Leberschädigung durch Äthionamid. Dtsch Med Wochenschr 92: 1718PubMedCrossRefGoogle Scholar
  43. 22.
    Meyler LA, Herx Heimer (1968/1972) Side effect of drugs, vol 6 and 7. Excerpta Medica Foundation, AmsterdamGoogle Scholar
  44. 23.
    Zankl E, Wiechert E (1972) Leberverträglichkeit von Prothionamid Prax Pneumol 26: 450Google Scholar
  45. 24.
    Snodgrass, WR, Potter WZ, Timbrell JA, Jollow DJ, Mitchell JR (1974) Possible mechanisms of isoniazid-related hepatic injury. Clin Res 22: 323A (Abstract)Google Scholar
  46. 25.
    Davies M, Williams R, Burley DM (1976) Rifampicin and enzyme induction. Med Chir Dig 5: 391–393Google Scholar
  47. 26.
    Dold U, Held H, v. Oldershausen HF (1970) Experimentelle Beobachtung zur Entstehung von Nebenwirkungen tuberculostatischer Therapie. Therapiewoche 20: 314Google Scholar
  48. 27.
    Adlercreutz H, Tenhunen R (1970) Some aspects of the interaction between natural and synthectic female sex hormons and the liver. Am J Med 49: 630–648PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1984

Authors and Affiliations

  • A. Doermer
    • 1
  • E. Ungeheuer
    • 1
  • M. Goerig
    • 2
  • A. Habenicht
    • 2
  • U. Tochtermann
    • 2
  • B. Kommerell
    • 2
  • B. Braun
    • 3
  • P. Meyer
    • 3
  • N. Börner
    • 3
  • H. Klusemann
    • 4
  • J. Reuß
    • 3
  • M. Rothmund
    • 5
  • H. Schomerus
    • 6
  • R. Heinrich
    • 6
  • W. Grauer
    • 6
  • A. Huber
    • 6
  • W. Fleckenstein
    • 6
  • Ch. Weiss
    • 6
  • E. Musch
    • 7
  • R. Stiens
    • 8
  • W. K. Lelbach
    • 7
  1. 1.Chirurgische KlinikNordwest-KrankenhausFrankfurt/MainDeutschland
  2. 2.Ludolf-Krehl-KlinikMed. Univ.KlinikHeidelbergDeutschland
  3. 3.II. Med. Univ.-Klinik MainzDeutschland
  4. 4.StrahlenkundeInstitut f. KlinDeutschland
  5. 5.Chirurg. Univ.-KlinikMainzDeutschland
  6. 6.Medizinische Universitätsklinik Tübingen und Institut für PhysiologieMedizinische HochschuleLübeckDeutschland
  7. 7.Bonn-VenusbergMed. Univ.-KlinikDeutschland
  8. 8.Pathologisches InstitutUniversität BonnDeutschland

Personalised recommendations